Diversion proctitis during staged restorative proctocolectomy with ileal pouch anal anastomosis is not associated with subsequent cuffitis Authors: Ishaan Dharia, Michael Plietz, Sue Hahn, Sergey Khaitov, Patricia Sylla, Alexander Greenstein, Marla C Dubinsky, Maia Kayal Published: 2026 ABSTRACT AbstractAimThe aim of this study was to assess the impact of diversion proctitis (DP) between the first and second surgical stage on pouch outcomes in patients with ulcerative colitis (UC) who underwent three-stage restorative proctocolectomy (RPC) with ileal pouch anal anastomosis (IPAA).MethodsWe conducted a retrospective chart review of patients with UC who underwent three stage RPC with IPAA followed by at least one pouchoscopy at Mount Sinai Hospital between 1/2008 and 12/2020. DP was defined as the presence of mucosal atrophy and lymphoid hyperplasia on proctectomy specimen as noted by the reporting pathologist. The primary outcome was cuffitis defined as ulceration of the cuff as reported during pouchoscopy. Continuous and categorical variables were analyzed with t-tests and chi-squared tests, respectively.ResultsOf the 281 patients included in this study, 68 (24.2%) were found to have DP. Age, sex, race, ethnicity, anastomosis type, and disease duration were not significant risk factors for DP development. More patients with vs without DP had evidence of severe disease pre-colectomy with admission for acute severe ulcerative colitis, steroids, and infliximab, though this did not reach statistical significance. A significantly greater proportion of patients with vs without DP required rectal therapy between the first and second surgical stages (32.4% vs 19.2%, p = 0.02). There was no significant difference in the development of cuffitis among patients with vs without DP (19.1% vs 14.1%, p = 0.32).ConclusionThe occurrence of DP between the first and second surgical stage of RPC with IPAA is significantly associated with the need for rectal therapy; however, is not associated with subsequent cuffitis.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00384-026-05182-y.Keywords: Ileal pouch anal anastomosis, Cuffitis, Diversion proctitis, Ulcerative colitis, Restorative proctocolectomy Introduction The treatment algorithm for ulcerative colitis (UC) continues to shift with the introduction of new therapies, however, the standard treatment for medically refractory disease or neoplasia remains surgical intervention [1]. The most common surgical intervention is the restorative proctocolectomy (RPC) with ileal pouch anal anastomosis (IPAA) performed in a two or three stage approach. The three stage approach involves (1) subtotal colectomy, end ileostomy, and rectal oversewing, (2) completion proctectomy, ileal pouch construction, anastomosis of the pouch to the rectal cuff, and diverting ileostomy, and (3) ileostomy closure [2]. The staged approach provides patients with sufficient time to taper steroids and optimize wound healing before proctectomy and pouch construction. [3]. Diversion proctitis (DP), defined as inflammation of the defunctionalized rectum between the first and second stage, occurs frequently in patients with UC who undergo staged RPC with IPAA, with an incidence of up to 87% [4–7]. Symptoms of DP include tenesmus, hematochezia, and mucoid discharge and compound those of ulcerative proctitis [7]. Although the exact pathophysiology has not been fully elucidated, DP is distinct from ulcerative proctitis and thought to be secondary to changes in the rectal flora and associated reductions in short-chain fatty acids (SCFAs), particularly butyrate, normally produced by bacterial fermentation of dietary fiber [8]. The development of DP in patients with UC, specifically, may be further driven by immune-mediated mechanisms as the incidence of DP is greater in patients who require diversion secondary to UC compared to those who require it secondary to malignancy or diverticular disease. [6, 7]. To date, there is limited data regarding the factors associated with the development of DP, and its long-term implications in patients with UC who require RPC with IPAA. The aim of this study was to assess the clinical factors associated with the development of DP and to investigate the short- and long-term implications of DP on pouch function and survival. Given that the cuff is residual rectum, we hypothesized that DP predisposed to the subsequent development of cuffitis. Methods This was a retrospective cohort analysis of patients over the age of 18 with UC who underwent a three stage RPC with IPAA at Mount Sinai Hospital for medically refractory disease or dysplasia between January 2008 and December 2020. Only patients who underwent pouchoscopy at any point after ileostomy closure were included. This retrospective research was approved by the Mount Sinai IRB, Study-16–01321 and was reported according to the STROBE guidelines. Clinical and surgical characteristics were reviewed and collected, including age, gender, race, pre-colectomy therapies, number of surgical stages, and duration of diversion. Pathology reports were reviewed, and the presence of DP was defined as the presence of mucosal atrophy and lymphoid hyperplasia on proctectomy specimen as noted by the reporting pathologist. Pouchoscopy reports were reviewed to assess the impact of DP on pouch outcomes after ileostomy closure. The primary outcome was cuffitis defined as ulceration of the cuff. Secondary outcomes included pouchitis defined as ulceration of the pouch body (excluding the suture lines) as reported by the performing gastroenterologist, anastomotic leak defined as an anastomotic site defect that caused leakage of luminal contents, and pouch failure defined as the need for pouch excision and a permanent end ileostomy. Continuous and categorical variables were analyzed with t-tests and chi-squared tests, respectively. Results A total of 794 patients underwent RPC with IPAA between January 2008 and December 2020. Of these, 281 underwent a three stage RPC with IPAA and had a follow-up pouchoscopy at Mount Sinai Hospital over a median follow-up of 31 months [IQR 16–55]. The median age at the time of colectomy was 32.0 years [IQR 22–44] and 146 (52.0%) patients were male. The indication for RPC with IPAA was medically refractory disease in 262 (93.2%) patients. The median pre-colectomy disease duration was 48 months [IQR 18–96] and 195 (69.4%) patients had pancolitis. A stapled (vs. handsewn) IPAA anastomosis was completed in 229 (81.5%) patients, and the median cuff length was 2 cm [IQR 2–3]. The median duration of diversion between the first and second surgical stage was 2 months [IQR 1–3]. Additional clinical characteristics are detailed in Table 1. Table 1Cohort characteristicsNo diversion proctitisDiversion proctitisp-valuen = 281n%n%n21375.8%6824.2%Median age (years)31330.80Sex Male11051.6%3652.9%0.85Ethnicity0.25 Hispanic or Latino125.6%57.4% Not Hispanic or Latino16979.3%5885.3% Unknown/not reported3215.0%57.4%Race0.80 Black or African American62.8%34.4% White16778.4%5377.9% Other/unknown4018.8%1217.6%Median disease duration (months)48360.57Pre-colectomy steroid use16175.6%5885.3%0.09Pre-colectomy biologic/small molecule use14869.5%5073.5%0.52 Adalimumab3315.5%68.8%0.17 Infliximab9544.6%3957.4%0.07 Vedolizumab4119.2%1420.6%0.81 Ustekinumab41.9%11.5%0.82 Tofacitinib125.6%57.4%0.60 Other31.4%22.9%0.41Admitted for acute severe ulcerative colitis7133.3%3145.6%0.07Disease classification0.48 Ulcerative proctitis146.6%68.8% Left sided UC (distal UC)3215.0%1420.6% Extensive UC (pancolitis)15371.8%4261.8% IBDU (unclassified) or unknown146.6%68.8%Indication for colectomy0.67 Medically refractory UC19792.5%6595.6% Dysplasia/cancer115.2%22.9% Other/unknown52.3%11.5%IPAA anastomosis0.49 Stapled17381.2%5682.4% Handsewn3315.5%811.8%Median duration of diversion (months)220.57Median cuff length (cm)220.47Required rectal therapy between 1 st and 2nd stage4119.2%2232.4%0.02 Cohort characteristics Diversion proctitis was noted in 68 (24.2%) patients. Age, sex, race, ethnicity, anastomosis type, disease duration, and IPAA indication were not significant risk factors for DP development. More patients with vs without DP had evidence of severe disease pre-colectomy with admission for acute severe ulcerative colitis (45.6% vs 33.3%, p = 0.07), intravenous steroids (85.3% vs 75.6%, p = 0.09), and infliximab (57.4% vs 44.6%, p = 0.07), though this did not reach statistical significance. The use of other biologics or small-molecule therapies, including vedolizumab, ustekinumab, and tofacitinib, was similar between groups. In terms of surgical characteristics, the median duration of diversion was 2 months in each group and not significantly different among the patients with vs without DP (p = 0.57). Notably, a significantly greater proportion of patients with vs without DP required rectal therapy between the first and second surgical stage for urgency and mucoid discharge (32.4 vs 19.2%, p = 0.02). Rectal therapies included mesalamine, steroid, and SCFA enemas. Among those treated, 88% noted improvement in rectal bleeding, mucoid discharge, and perineal pain. There was no significant difference in the frequency of anastomotic leaks after the first stage among patients with vs without DP (1.5 vs 1.9%, p = 0.82). There was no significant difference in the frequency of subsequent cuffitis (19.1% vs 14.1%, p = 0.32) or pouchitis (26.5% vs 26.3%, p = 0.98) among patients with vs without DP (Table 2). Importantly, DP was not significantly associated with anastomotic leak (1.5% vs 1.9%, p = 0.82) or pouch failure (5.9% vs 9.9%, p = 0.32) among patients with vs without DP (Table 2). Table 2Post-IPAA complicationsNo diversion proctitisWith diversion proctitisp-valueCuffitis3014.1%1319.1%0.32Pouchitis5626.3%1826.5%0.98Anastomotic leak41.9%11.5%0.82Pouch failure219.9%45.9%0.32 Post-IPAA complications Discussion and conclusions Little is known about the impact of DP on short- and long-term pouch outcomes [6]. In this study of 281 patients with UC who underwent three-stage RPC with IPAA, DP developed in approximately 20% after colectomy and end ileostomy and was significantly associated with the need for rectal therapy between the first and second surgical stage. These results suggest symptoms of urgency and mucoid discharge that occur between surgical stages may be more attributable to DP rather than ongoing ulcerative proctitis. This is particularly important as the accurate identification of DP ensures targeted therapies such as SCFA enemas are appropriately utilized, rather than those reserved for active UC such as steroids, biologics, or small molecules. There was a non-significant signal that suggested disease severity prior to RPC with IPAA was associated with the development of DP. Specifically, more patients with vs without DP had evidence of severe disease pre-colectomy with admission for acute severe ulcerative colitis, intravenous steroids, and infliximab in the three months prior to colectomy. The impact of pre-colectomy disease on the development of DP has similarly been reported by Fu et al. In a histologic analysis of diverted colon specimens from patients with (n = 79) and without (n = 80) inflammatory bowel disease and the corresponding colectomy specimens (n = 52), the severity of activity in diverted segments correlated with the severity of inflammation in both colectomy specimens and their distal margins [9]. In aggregate, the results of this study and that by Fu et al. suggest that the severity of inflammation prior to RPC with IPAA may predispose to a residual inflammatory milieu at the site of diversion that ultimately results in DP. Importantly, there was no significant association between DP and subsequent cuffitis. Cuffitis occurs in up to 60% of patients post-IPAA and presents with symptoms of proctitis such as hematochezia and tenesmus [10]. Although the cuff is constructed from the residual 1–3 cm of rectum that may be impacted by DP during staged RPC with IPAA, the lack of association between DP and cuffitis underscores separate pathophysiologic processes. Cuffitis is likely driven by immune-mediated mechanisms similar to ulcerative proctitis, while DP is driven by reductions in SCFAs. Likewise, there was no significant association between DP and subsequent pouchitis, in line with previous findings by Wasmann et al. [6]. The strengths of this study include the large sample size, standardized outcomes, and clinical relevance. The major limitations include its retrospective nature, lack of standardized objective criteria for the diagnosis of DP, and variation in follow-up. Furthermore, although all specimens were reviewed by pathologists specialized in IBD, reports were not synoptic and DP was reported only when present. Despite these acknowledged limitations, the study still presents important and actionable insights. Symptoms of urgency and mucoid discharge between the first and second surgical stage in patients with UC who are undergoing RPC with IPAA should not be automatically attributed to residual ulcerative proctitis. Rather, the differential should include DP and appropriate therapy with SCFA enemas should be considered. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOC 83 kb) Author contributions ID: study concept and design, acquisition of data, analysis and interpretation of data, drafting of manuscript, critical revision of the manuscript for important intellectual content; MP: acquisition of data, critical revision of the manuscript for important intellectual content; SH: critical revision of the manuscript for important intellectual content; SK: critical revision of the manuscript for important intellectual content; SK: critical revision of the manuscript for important intellectual content; PS: critical revision of the manuscript for important intellectual content; AG: critical revision of the manuscript for important intellectual content; MCD: critical revision of the manuscript for important intellectual content; MK: study concept and design, acquisition of data, analysis and interpretation of data, critical revision of the manuscript for important intellectual content. Funding This work was supported by the NIH grant K23DK127241 (MK). The funder had no role in study design, execution, analysis, and manuscript conception, planning, writing, or decision to publish. Data availability Data are not publicly available for sharing due to privacy reasons. Data may be made available by request to the corresponding author. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary file1 (DOC 83 kb) Data Availability Statement Data are not publicly available for sharing due to privacy reasons. Data may be made available by request to the corresponding author.